img

Global Cytomegalovirus (CMV) Vaccine Market Research Report 2024


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Cytomegalovirus (CMV) Vaccine Market Research Report 2024

Cytomegalovirus (CMV) also known as HCMV, or Human Herpesvirus 5 (HHV-5) is the virus most commonly transmitted to a developing fetus. It is a common virus that infects people of all ages. According to the CDC, over half of adults by age 40 have been infected with CMV. Most people infected with CMV show no signs or symptoms. Whereas when a baby is born with cytomegalovirus (CMV) infection, it is called congenital CMV. Each year, approximately 5,000 infants in the U.S. may develop permanent problems due to CMV, some of the severe problems, includes deafness, blindness, and mental retardation. Furthermore, the global prevalence of congenital cytomegalovirus is said to be 0.3 – 2.0%. The Institute of Medicine (IOM) of the National Academy of Sciences, has designated CMV as a “highest priority” category for vaccine development, citing the years of life and disability that could be saved.
According to Mr Accuracy reports new survey, global Cytomegalovirus (CMV) Vaccine market is projected to reach US$ 205.9 million in 2029, increasing from US$ 153 million in 2022, with the CAGR of 4.4% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Cytomegalovirus (CMV) Vaccine market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Cytomegalovirus (CMV) Vaccine market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.



By Company


Merck
AlphaVax
Moderna
Novartis
Segment by Type
Attenuated Vaccines
Subunit Vaccines

Segment by Application


Laboratories
Hospitals
Diagnostic Centers and Clinics
Others

Consumption by Region


North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Cytomegalovirus (CMV) Vaccine report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source

Table of Content

1 Cytomegalovirus (CMV) Vaccine Market Overview
1.1 Product Overview and Scope of Cytomegalovirus (CMV) Vaccine
1.2 Cytomegalovirus (CMV) Vaccine Segment by Type
1.2.1 Global Cytomegalovirus (CMV) Vaccine Market Value Comparison by Type (2024-2034)
1.2.2 Attenuated Vaccines
1.2.3 Subunit Vaccines
1.3 Cytomegalovirus (CMV) Vaccine Segment by Application
1.3.1 Global Cytomegalovirus (CMV) Vaccine Market Value by Application: (2024-2034)
1.3.2 Laboratories
1.3.3 Hospitals
1.3.4 Diagnostic Centers and Clinics
1.3.5 Others
1.4 Global Cytomegalovirus (CMV) Vaccine Market Size Estimates and Forecasts
1.4.1 Global Cytomegalovirus (CMV) Vaccine Revenue 2018-2029
1.4.2 Global Cytomegalovirus (CMV) Vaccine Sales 2018-2029
1.4.3 Global Cytomegalovirus (CMV) Vaccine Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Cytomegalovirus (CMV) Vaccine Market Competition by Manufacturers
2.1 Global Cytomegalovirus (CMV) Vaccine Sales Market Share by Manufacturers (2018-2024)
2.2 Global Cytomegalovirus (CMV) Vaccine Revenue Market Share by Manufacturers (2018-2024)
2.3 Global Cytomegalovirus (CMV) Vaccine Average Price by Manufacturers (2018-2024)
2.4 Global Cytomegalovirus (CMV) Vaccine Industry Ranking 2021 VS 2022 VS 2024
2.5 Global Key Manufacturers of Cytomegalovirus (CMV) Vaccine, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Cytomegalovirus (CMV) Vaccine, Product Type & Application
2.7 Cytomegalovirus (CMV) Vaccine Market Competitive Situation and Trends
2.7.1 Cytomegalovirus (CMV) Vaccine Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Cytomegalovirus (CMV) Vaccine Players Market Share by Revenue
2.7.3 Global Cytomegalovirus (CMV) Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Cytomegalovirus (CMV) Vaccine Retrospective Market Scenario by Region
3.1 Global Cytomegalovirus (CMV) Vaccine Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Cytomegalovirus (CMV) Vaccine Global Cytomegalovirus (CMV) Vaccine Sales by Region: 2018-2029
3.2.1 Global Cytomegalovirus (CMV) Vaccine Sales by Region: 2018-2024
3.2.2 Global Cytomegalovirus (CMV) Vaccine Sales by Region: 2024-2029
3.3 Global Cytomegalovirus (CMV) Vaccine Global Cytomegalovirus (CMV) Vaccine Revenue by Region: 2018-2029
3.3.1 Global Cytomegalovirus (CMV) Vaccine Revenue by Region: 2018-2024
3.3.2 Global Cytomegalovirus (CMV) Vaccine Revenue by Region: 2024-2029
3.4 North America Cytomegalovirus (CMV) Vaccine Market Facts & Figures by Country
3.4.1 North America Cytomegalovirus (CMV) Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Cytomegalovirus (CMV) Vaccine Sales by Country (2018-2029)
3.4.3 North America Cytomegalovirus (CMV) Vaccine Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Cytomegalovirus (CMV) Vaccine Market Facts & Figures by Country
3.5.1 Europe Cytomegalovirus (CMV) Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Cytomegalovirus (CMV) Vaccine Sales by Country (2018-2029)
3.5.3 Europe Cytomegalovirus (CMV) Vaccine Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Cytomegalovirus (CMV) Vaccine Market Facts & Figures by Country
3.6.1 Asia Pacific Cytomegalovirus (CMV) Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Cytomegalovirus (CMV) Vaccine Sales by Country (2018-2029)
3.6.3 Asia Pacific Cytomegalovirus (CMV) Vaccine Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Cytomegalovirus (CMV) Vaccine Market Facts & Figures by Country
3.7.1 Latin America Cytomegalovirus (CMV) Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Cytomegalovirus (CMV) Vaccine Sales by Country (2018-2029)
3.7.3 Latin America Cytomegalovirus (CMV) Vaccine Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Cytomegalovirus (CMV) Vaccine Market Facts & Figures by Country
3.8.1 Middle East and Africa Cytomegalovirus (CMV) Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Cytomegalovirus (CMV) Vaccine Sales by Country (2018-2029)
3.8.3 Middle East and Africa Cytomegalovirus (CMV) Vaccine Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Cytomegalovirus (CMV) Vaccine Sales by Type (2018-2029)
4.1.1 Global Cytomegalovirus (CMV) Vaccine Sales by Type (2018-2024)
4.1.2 Global Cytomegalovirus (CMV) Vaccine Sales by Type (2024-2029)
4.1.3 Global Cytomegalovirus (CMV) Vaccine Sales Market Share by Type (2018-2029)
4.2 Global Cytomegalovirus (CMV) Vaccine Revenue by Type (2018-2029)
4.2.1 Global Cytomegalovirus (CMV) Vaccine Revenue by Type (2018-2024)
4.2.2 Global Cytomegalovirus (CMV) Vaccine Revenue by Type (2024-2029)
4.2.3 Global Cytomegalovirus (CMV) Vaccine Revenue Market Share by Type (2018-2029)
4.3 Global Cytomegalovirus (CMV) Vaccine Price by Type (2018-2029)
5 Segment by Application
5.1 Global Cytomegalovirus (CMV) Vaccine Sales by Application (2018-2029)
5.1.1 Global Cytomegalovirus (CMV) Vaccine Sales by Application (2018-2024)
5.1.2 Global Cytomegalovirus (CMV) Vaccine Sales by Application (2024-2029)
5.1.3 Global Cytomegalovirus (CMV) Vaccine Sales Market Share by Application (2018-2029)
5.2 Global Cytomegalovirus (CMV) Vaccine Revenue by Application (2018-2029)
5.2.1 Global Cytomegalovirus (CMV) Vaccine Revenue by Application (2018-2024)
5.2.2 Global Cytomegalovirus (CMV) Vaccine Revenue by Application (2024-2029)
5.2.3 Global Cytomegalovirus (CMV) Vaccine Revenue Market Share by Application (2018-2029)
5.3 Global Cytomegalovirus (CMV) Vaccine Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Merck
6.1.1 Merck Corporation Information
6.1.2 Merck Description and Business Overview
6.1.3 Merck Cytomegalovirus (CMV) Vaccine Sales, Revenue and Gross Margin (2018-2024)
6.1.4 Merck Cytomegalovirus (CMV) Vaccine Product Portfolio
6.1.5 Merck Recent Developments/Updates
6.2 AlphaVax
6.2.1 AlphaVax Corporation Information
6.2.2 AlphaVax Description and Business Overview
6.2.3 AlphaVax Cytomegalovirus (CMV) Vaccine Sales, Revenue and Gross Margin (2018-2024)
6.2.4 AlphaVax Cytomegalovirus (CMV) Vaccine Product Portfolio
6.2.5 AlphaVax Recent Developments/Updates
6.3 Moderna
6.3.1 Moderna Corporation Information
6.3.2 Moderna Description and Business Overview
6.3.3 Moderna Cytomegalovirus (CMV) Vaccine Sales, Revenue and Gross Margin (2018-2024)
6.3.4 Moderna Cytomegalovirus (CMV) Vaccine Product Portfolio
6.3.5 Moderna Recent Developments/Updates
6.4 Novartis
6.4.1 Novartis Corporation Information
6.4.2 Novartis Description and Business Overview
6.4.3 Novartis Cytomegalovirus (CMV) Vaccine Sales, Revenue and Gross Margin (2018-2024)
6.4.4 Novartis Cytomegalovirus (CMV) Vaccine Product Portfolio
6.4.5 Novartis Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Cytomegalovirus (CMV) Vaccine Industry Chain Analysis
7.2 Cytomegalovirus (CMV) Vaccine Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Cytomegalovirus (CMV) Vaccine Production Mode & Process
7.4 Cytomegalovirus (CMV) Vaccine Sales and Marketing
7.4.1 Cytomegalovirus (CMV) Vaccine Sales Channels
7.4.2 Cytomegalovirus (CMV) Vaccine Distributors
7.5 Cytomegalovirus (CMV) Vaccine Customers
8 Cytomegalovirus (CMV) Vaccine Market Dynamics
8.1 Cytomegalovirus (CMV) Vaccine Industry Trends
8.2 Cytomegalovirus (CMV) Vaccine Market Drivers
8.3 Cytomegalovirus (CMV) Vaccine Market Challenges
8.4 Cytomegalovirus (CMV) Vaccine Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

List of Figure

List of Tables
Table 1. Global Cytomegalovirus (CMV) Vaccine Market Value Comparison by Type (2024-2034) & (US$ Million)
Table 2. Global Cytomegalovirus (CMV) Vaccine Market Value Comparison by Application (2024-2034) & (US$ Million)
Table 3. Global Cytomegalovirus (CMV) Vaccine Market Competitive Situation by Manufacturers in 2022
Table 4. Global Cytomegalovirus (CMV) Vaccine Sales (K Doses) of Key Manufacturers (2018-2024)
Table 5. Global Cytomegalovirus (CMV) Vaccine Sales Market Share by Manufacturers (2018-2024)
Table 6. Global Cytomegalovirus (CMV) Vaccine Revenue (US$ Million) by Manufacturers (2018-2024)
Table 7. Global Cytomegalovirus (CMV) Vaccine Revenue Share by Manufacturers (2018-2024)
Table 8. Global Market Cytomegalovirus (CMV) Vaccine Average Price (US$/Dose) of Key Manufacturers (2018-2024)
Table 9. Global Key Players of Cytomegalovirus (CMV) Vaccine, Industry Ranking, 2021 VS 2022 VS 2024
Table 10. Global Key Manufacturers of Cytomegalovirus (CMV) Vaccine, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Cytomegalovirus (CMV) Vaccine, Product Type & Application
Table 12. Global Key Manufacturers of Cytomegalovirus (CMV) Vaccine, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Cytomegalovirus (CMV) Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cytomegalovirus (CMV) Vaccine as of 2022)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Cytomegalovirus (CMV) Vaccine Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 17. Global Cytomegalovirus (CMV) Vaccine Sales by Region (2018-2024) & (K Doses)
Table 18. Global Cytomegalovirus (CMV) Vaccine Sales Market Share by Region (2018-2024)
Table 19. Global Cytomegalovirus (CMV) Vaccine Sales by Region (2024-2029) & (K Doses)
Table 20. Global Cytomegalovirus (CMV) Vaccine Sales Market Share by Region (2024-2029)
Table 21. Global Cytomegalovirus (CMV) Vaccine Revenue by Region (2018-2024) & (US$ Million)
Table 22. Global Cytomegalovirus (CMV) Vaccine Revenue Market Share by Region (2018-2024)
Table 23. Global Cytomegalovirus (CMV) Vaccine Revenue by Region (2024-2029) & (US$ Million)
Table 24. Global Cytomegalovirus (CMV) Vaccine Revenue Market Share by Region (2024-2029)
Table 25. North America Cytomegalovirus (CMV) Vaccine Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 26. North America Cytomegalovirus (CMV) Vaccine Sales by Country (2018-2024) & (K Doses)
Table 27. North America Cytomegalovirus (CMV) Vaccine Sales by Country (2024-2029) & (K Doses)
Table 28. North America Cytomegalovirus (CMV) Vaccine Revenue by Country (2018-2024) & (US$ Million)
Table 29. North America Cytomegalovirus (CMV) Vaccine Revenue by Country (2024-2029) & (US$ Million)
Table 30. Europe Cytomegalovirus (CMV) Vaccine Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 31. Europe Cytomegalovirus (CMV) Vaccine Sales by Country (2018-2024) & (K Doses)
Table 32. Europe Cytomegalovirus (CMV) Vaccine Sales by Country (2024-2029) & (K Doses)
Table 33. Europe Cytomegalovirus (CMV) Vaccine Revenue by Country (2018-2024) & (US$ Million)
Table 34. Europe Cytomegalovirus (CMV) Vaccine Revenue by Country (2024-2029) & (US$ Million)
Table 35. Asia Pacific Cytomegalovirus (CMV) Vaccine Revenue by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 36. Asia Pacific Cytomegalovirus (CMV) Vaccine Sales by Region (2018-2024) & (K Doses)
Table 37. Asia Pacific Cytomegalovirus (CMV) Vaccine Sales by Region (2024-2029) & (K Doses)
Table 38. Asia Pacific Cytomegalovirus (CMV) Vaccine Revenue by Region (2018-2024) & (US$ Million)
Table 39. Asia Pacific Cytomegalovirus (CMV) Vaccine Revenue by Region (2024-2029) & (US$ Million)
Table 40. Latin America Cytomegalovirus (CMV) Vaccine Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 41. Latin America Cytomegalovirus (CMV) Vaccine Sales by Country (2018-2024) & (K Doses)
Table 42. Latin America Cytomegalovirus (CMV) Vaccine Sales by Country (2024-2029) & (K Doses)
Table 43. Latin America Cytomegalovirus (CMV) Vaccine Revenue by Country (2018-2024) & (US$ Million)
Table 44. Latin America Cytomegalovirus (CMV) Vaccine Revenue by Country (2024-2029) & (US$ Million)
Table 45. Middle East & Africa Cytomegalovirus (CMV) Vaccine Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 46. Middle East & Africa Cytomegalovirus (CMV) Vaccine Sales by Country (2018-2024) & (K Doses)
Table 47. Middle East & Africa Cytomegalovirus (CMV) Vaccine Sales by Country (2024-2029) & (K Doses)
Table 48. Middle East & Africa Cytomegalovirus (CMV) Vaccine Revenue by Country (2018-2024) & (US$ Million)
Table 49. Middle East & Africa Cytomegalovirus (CMV) Vaccine Revenue by Country (2024-2029) & (US$ Million)
Table 50. Global Cytomegalovirus (CMV) Vaccine Sales (K Doses) by Type (2018-2024)
Table 51. Global Cytomegalovirus (CMV) Vaccine Sales (K Doses) by Type (2024-2029)
Table 52. Global Cytomegalovirus (CMV) Vaccine Sales Market Share by Type (2018-2024)
Table 53. Global Cytomegalovirus (CMV) Vaccine Sales Market Share by Type (2024-2029)
Table 54. Global Cytomegalovirus (CMV) Vaccine Revenue (US$ Million) by Type (2018-2024)
Table 55. Global Cytomegalovirus (CMV) Vaccine Revenue (US$ Million) by Type (2024-2029)
Table 56. Global Cytomegalovirus (CMV) Vaccine Revenue Market Share by Type (2018-2024)
Table 57. Global Cytomegalovirus (CMV) Vaccine Revenue Market Share by Type (2024-2029)
Table 58. Global Cytomegalovirus (CMV) Vaccine Price (US$/Dose) by Type (2018-2024)
Table 59. Global Cytomegalovirus (CMV) Vaccine Price (US$/Dose) by Type (2024-2029)
Table 60. Global Cytomegalovirus (CMV) Vaccine Sales (K Doses) by Application (2018-2024)
Table 61. Global Cytomegalovirus (CMV) Vaccine Sales (K Doses) by Application (2024-2029)
Table 62. Global Cytomegalovirus (CMV) Vaccine Sales Market Share by Application (2018-2024)
Table 63. Global Cytomegalovirus (CMV) Vaccine Sales Market Share by Application (2024-2029)
Table 64. Global Cytomegalovirus (CMV) Vaccine Revenue (US$ Million) by Application (2018-2024)
Table 65. Global Cytomegalovirus (CMV) Vaccine Revenue (US$ Million) by Application (2024-2029)
Table 66. Global Cytomegalovirus (CMV) Vaccine Revenue Market Share by Application (2018-2024)
Table 67. Global Cytomegalovirus (CMV) Vaccine Revenue Market Share by Application (2024-2029)
Table 68. Global Cytomegalovirus (CMV) Vaccine Price (US$/Dose) by Application (2018-2024)
Table 69. Global Cytomegalovirus (CMV) Vaccine Price (US$/Dose) by Application (2024-2029)
Table 70. Merck Corporation Information
Table 71. Merck Description and Business Overview
Table 72. Merck Cytomegalovirus (CMV) Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2018-2024)
Table 73. Merck Cytomegalovirus (CMV) Vaccine Product
Table 74. Merck Recent Developments/Updates
Table 75. AlphaVax Corporation Information
Table 76. AlphaVax Description and Business Overview
Table 77. AlphaVax Cytomegalovirus (CMV) Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2018-2024)
Table 78. AlphaVax Cytomegalovirus (CMV) Vaccine Product
Table 79. AlphaVax Recent Developments/Updates
Table 80. Moderna Corporation Information
Table 81. Moderna Description and Business Overview
Table 82. Moderna Cytomegalovirus (CMV) Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2018-2024)
Table 83. Moderna Cytomegalovirus (CMV) Vaccine Product
Table 84. Moderna Recent Developments/Updates
Table 85. Novartis Corporation Information
Table 86. Novartis Description and Business Overview
Table 87. Novartis Cytomegalovirus (CMV) Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2018-2024)
Table 88. Novartis Cytomegalovirus (CMV) Vaccine Product
Table 89. Novartis Recent Developments/Updates
Table 90. Key Raw Materials Lists
Table 91. Raw Materials Key Suppliers Lists
Table 92. Cytomegalovirus (CMV) Vaccine Distributors List
Table 93. Cytomegalovirus (CMV) Vaccine Customers List
Table 94. Cytomegalovirus (CMV) Vaccine Market Trends
Table 95. Cytomegalovirus (CMV) Vaccine Market Drivers
Table 96. Cytomegalovirus (CMV) Vaccine Market Challenges
Table 97. Cytomegalovirus (CMV) Vaccine Market Restraints
Table 98. Research Programs/Design for This Report
Table 99. Key Data Information from Secondary Sources
Table 100. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Cytomegalovirus (CMV) Vaccine
Figure 2. Global Cytomegalovirus (CMV) Vaccine Market Value Comparison by Type (2024-2034) & (US$ Million)
Figure 3. Global Cytomegalovirus (CMV) Vaccine Market Share by Type in 2022 & 2029
Figure 4. Attenuated Vaccines Product Picture
Figure 5. Subunit Vaccines Product Picture
Figure 6. Global Cytomegalovirus (CMV) Vaccine Market Value Comparison by Application (2024-2034) & (US$ Million)
Figure 7. Global Cytomegalovirus (CMV) Vaccine Market Share by Application in 2022 & 2029
Figure 8. Laboratories
Figure 9. Hospitals
Figure 10. Diagnostic Centers and Clinics
Figure 11. Others
Figure 12. Global Cytomegalovirus (CMV) Vaccine Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 13. Global Cytomegalovirus (CMV) Vaccine Market Size (2018-2029) & (US$ Million)
Figure 14. Global Cytomegalovirus (CMV) Vaccine Sales (2018-2029) & (K Doses)
Figure 15. Global Cytomegalovirus (CMV) Vaccine Average Price (US$/Dose) & (2018-2029)
Figure 16. Cytomegalovirus (CMV) Vaccine Report Years Considered
Figure 17. Cytomegalovirus (CMV) Vaccine Sales Share by Manufacturers in 2022
Figure 18. Global Cytomegalovirus (CMV) Vaccine Revenue Share by Manufacturers in 2022
Figure 19. The Global 5 and 10 Largest Cytomegalovirus (CMV) Vaccine Players: Market Share by Revenue in 2022
Figure 20. Cytomegalovirus (CMV) Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022
Figure 21. Global Cytomegalovirus (CMV) Vaccine Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Figure 22. North America Cytomegalovirus (CMV) Vaccine Sales Market Share by Country (2018-2029)
Figure 23. North America Cytomegalovirus (CMV) Vaccine Revenue Market Share by Country (2018-2029)
Figure 24. United States Cytomegalovirus (CMV) Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 25. Canada Cytomegalovirus (CMV) Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 26. Europe Cytomegalovirus (CMV) Vaccine Sales Market Share by Country (2018-2029)
Figure 27. Europe Cytomegalovirus (CMV) Vaccine Revenue Market Share by Country (2018-2029)
Figure 28. Germany Cytomegalovirus (CMV) Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 29. France Cytomegalovirus (CMV) Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 30. U.K. Cytomegalovirus (CMV) Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 31. Italy Cytomegalovirus (CMV) Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 32. Russia Cytomegalovirus (CMV) Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 33. Asia Pacific Cytomegalovirus (CMV) Vaccine Sales Market Share by Region (2018-2029)
Figure 34. Asia Pacific Cytomegalovirus (CMV) Vaccine Revenue Market Share by Region (2018-2029)
Figure 35. China Cytomegalovirus (CMV) Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 36. Japan Cytomegalovirus (CMV) Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 37. South Korea Cytomegalovirus (CMV) Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 38. India Cytomegalovirus (CMV) Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 39. Australia Cytomegalovirus (CMV) Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 40. China Taiwan Cytomegalovirus (CMV) Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 41. Indonesia Cytomegalovirus (CMV) Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 42. Thailand Cytomegalovirus (CMV) Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 43. Malaysia Cytomegalovirus (CMV) Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 44. Latin America Cytomegalovirus (CMV) Vaccine Sales Market Share by Country (2018-2029)
Figure 45. Latin America Cytomegalovirus (CMV) Vaccine Revenue Market Share by Country (2018-2029)
Figure 46. Mexico Cytomegalovirus (CMV) Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 47. Brazil Cytomegalovirus (CMV) Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 48. Argentina Cytomegalovirus (CMV) Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 49. Middle East & Africa Cytomegalovirus (CMV) Vaccine Sales Market Share by Country (2018-2029)
Figure 50. Middle East & Africa Cytomegalovirus (CMV) Vaccine Revenue Market Share by Country (2018-2029)
Figure 51. Turkey Cytomegalovirus (CMV) Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 52. Saudi Arabia Cytomegalovirus (CMV) Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 53. UAE Cytomegalovirus (CMV) Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 54. Global Sales Market Share of Cytomegalovirus (CMV) Vaccine by Type (2018-2029)
Figure 55. Global Revenue Market Share of Cytomegalovirus (CMV) Vaccine by Type (2018-2029)
Figure 56. Global Cytomegalovirus (CMV) Vaccine Price (US$/Dose) by Type (2018-2029)
Figure 57. Global Sales Market Share of Cytomegalovirus (CMV) Vaccine by Application (2018-2029)
Figure 58. Global Revenue Market Share of Cytomegalovirus (CMV) Vaccine by Application (2018-2029)
Figure 59. Global Cytomegalovirus (CMV) Vaccine Price (US$/Dose) by Application (2018-2029)
Figure 60. Cytomegalovirus (CMV) Vaccine Value Chain
Figure 61. Cytomegalovirus (CMV) Vaccine Production Process
Figure 62. Channels of Distribution (Direct Vs Distribution)
Figure 63. Distributors Profiles
Figure 64. Bottom-up and Top-down Approaches for This Report
Figure 65. Data Triangulation
Figure 66. Key Executives Interviewed